SMALLPOX TREATMENT MARKET ANALYSIS

Name: Smallpox Treatment Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Smallpox Treatment Market, By Treatment Type (Antiviral Drugs, Vaccination, Supportive Care), By Route of Administration (Oral, Injectable, Others (Topical, etc.)), By Distribution Channel (Hospitals (Public, Private), Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

New product Approval

In June 2021, Chimerix Inc., a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted TEMBEXA (brincidofovir) tablets and oral suspension approval for the treatment of smallpox in adult and pediatric patients.
In May 2022, GA Technologies, a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its intravenous (IV) formulation of TPOXX for the treatment of smallpox.

Acquisition

In September 2022, Emergent BioSolutions Inc., a U.S.-based multinational specialty biopharmaceutical company, announced that they had acquired exclusive worldwide rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox, from Chimerix Inc., a U.S.-based biopharmaceutical company.